3T Biosciences

3T Biosciences is an immunotherapy company based in South San Francisco, California, founded in 2017. The company focuses on developing targeted biotherapeutics for oncology and immune-mediated diseases, leveraging research from Dr. K. Christopher Garcia's lab at Stanford University. Their mission is to harness the immune system to create effective therapies for solid tumors and other challenging cancers.

The company utilizes its proprietary 3T-TRACE™ platform technology, which employs diverse target libraries and machine-learning algorithms to identify and validate T cell receptor (TCR) targets. Additionally, 3T Biosciences has developed the 3T-PRIME™ discovery platform to enhance its pipeline of TCR-based therapeutics. Their lead program, 3T-403, is a bispecific therapeutic currently in development, with plans to enter clinical trials for solid tumors in early 2026.

3T Biosciences has filed 10 patents, focusing on topics related to the immune system and immunology. The company is supported by a skilled management team and notable investors, including Westlake Village BioPartners and Lightspeed Venture Partners.